The DOI matches its Crossref record.
Increased cannabinoid CB1 receptor binding and activation of GTP‐binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP‐treated marmosets
Abstract
Recent evidence obtained in rat models of Parkinson's disease showed that the density of cannabinoid CB 1 receptors and their endogenous ligands increase in basal ganglia. However, no data exists from post‐mortem brain of humans affected by Parkinson's disease or from primate models of the disorder. In the present study, we examined CB 1 receptor binding and the magnitude of the stimulation by WIN55,212‐2, a specific CB 1 receptor agonist, of [35 S]GTPγS binding to membrane fractions from the basal ganglia of patients affected by Parkinson's disease. In Parkinson's disease, WIN55,212‐2‐stimulated [35 S]GTPγS binding in the caudate nucleus, putamen, lateral globus pallidus and substantia nigra was increased, thus indicating a more effective activation of GTP‐binding protein‐coupled signalling mechanisms via CB 1 receptors. This was accompanied by an increase in CB 1 receptor binding in the caudate nucleus and the putamen, although no changes were observed in the lateral globus pallidus and the substantia nigra. Because Parkinson's disease patients had been chronically treated with l‐DOPA, brains were studied from normal common marmosets and 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐treated animals with and without chronic L‐DOPA treatment. MPTP‐lesioned marmosets had increased CB 1 receptor binding in the caudate nucleus and the putamen compared to control marmosets, as well as increased stimulation of [35 S]GTPγS binding by WIN55,212‐2. However, following l‐DOPA treatment these parameters returned towards control values. The results indicate that a nigro‐striatal lesion is associated with an increase in CB 1 receptors in the basal ganglia in humans and nonhuman primates and that this increase could be reversed by chronic l‐DOPA therapy. The data suggest that CB 1 receptor blockade might be useful as an adjuvant for the treatment of parkinsonian motor symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Lastres-Becker, I., Molina-Holgado, F., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.11.009 · Cited by 407
Self-citationIannotti, F. A., Di Marzo, V., & Petrosino, S. (2016) · Progress in Lipid Research · doi:10.1016/j.plipres.2016.02.002 · Cited by 357
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H., & Brotchie, J. M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005678 · Cited by 324
The [35S]GTPγS binding assay: approaches and applications in pharmacology
Harrison, C., & Traynor, J. R. (2003) · Life Sciences · doi:10.1016/j.lfs.2003.07.005 · Cited by 302
Metadata
- Authors
- Lastres‐Becker, I., Cebeira, M., de Ceballos, M. L., Zeng, B. ‐., Jenner, P., Ramos, J. A., & Fernández‐Ruiz, J. J.
- Venue
- European Journal of Neuroscience
- Publisher
- Wiley
- Published
- 2001-12
- Volume
- 14
- Issue
- 11
- Pages
- 1827-1832
- ISSN
- 0953-816X (ISSN-L)
- 1460-9568
- OpenAlex
- W2020978550
- Cited by
- 185
- References
- 0
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Increased cannabinoid CB1 receptor binding and activation of GTP‐binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP‐treated marmosets. https://app.cochat.ai/papers/10.1046/j.0953-816x.2001.01812.x
- The paper
- Lastres‐Becker, I., Cebeira, M., de Ceballos, M. L., Zeng, B. ‐., Jenner, P., Ramos, J. A., & Fernández‐Ruiz, J. J. (2001). Increased cannabinoid CB1 receptor binding and activation of GTP‐binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP‐treated marmosets. European Journal of Neuroscience. https://doi.org/10.1046/j.0953-816x.2001.01812.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.